Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did these 2 items below occur and was this the outcome?
- If the Department determines that a request to process documentation related to a SEA Rule 10b-17 Action or a Other Company-Related Action is deficient, FINRA staff shall provide written notice to the Requesting Party. Any notice issued under this paragraph shall state the specific factor(s) that caused the request to be deemed deficient and the Requesting Party may appeal a determination pursuant to paragraph (e) of this Rule.
- Am I required to file an appeal to a FINRA Rule 6490(d) deficiency determination?
No. A requesting party is not required to appeal a deficiency finding. If a requesting party does not appeal a deficiency finding, the Department will not announce the requesting party’s Company Related Action.
Is this the week for the great AXXA turnaround? On the launchpad from $.004s to $.04s?
Why is CCAJ "Pink Limited Information" if they have such a good CEO and have an Auditor? What is going on here?
I'm getting a bit restless, even though planning to hang on the edge until 2024! I want to see if they can actually build anything since they are "a Builder primarily engaged in the construction of single-family houses (SIC 6552) and other buildings for sale" after all!
Now you can use those dividends to go to the Serenity Lakeside Resort in Thailand!
FINRA Information (below). Happy reading and I wonder where CCAJ is at in this process? Here is what CCAJ posted on their website under FAQs on March 31, 2023: "CCAC has been in contact with FINRA in regards to the Reverse Split and FINRA has made certain request in which the company is gathering the information requested to provide to FINRA."
FINRA Rule 6490. Processing of Company-Related Actions
(a) General
(1) In furtherance of FINRA's obligations to foster cooperation and coordination of the clearing, settling and processing of transactions in equity and debt securities of any issuer with a class of publicly traded, non-exchange listed, securities in the OTC market and, in general, to protect investors and the public interest, FINRA's Operations Department ("Department") reviews and processes documents related to announcements for SEA Rule 10b-17 Actions and Other Company-Related Actions to facilitate the orderly trading and settlement of OTC securities.
(2) For purposes of this Rule, the term "SEA Rule 10b-17 Actions" includes, dividends or other distributions in cash or kind, stock splits or reverse stock splits, or rights or other subscription offerings, and such other actions as are provided for in SEA Rule 10b-17; and the term "Other Company-Related Actions" includes, but is not limited to, any issuance or change to a symbol or name, mergers, acquisitions, dissolutions or other company control transactions; and bankruptcy or liquidations.
(3) This Rule details the advance notification, supporting documentation and fees required by FINRA to process documentation related to such requests.
(b) Request for FINRA Action
(1) An issuer or other duly authorized representative of the issuer may request that FINRA process documentation related to an SEA Rule 10b-17 Action or Other Company-Related Action by submitting a signed request in the manner and form required by FINRA ("Requesting Party"). Initial symbol set up requests may also be submitted by members or associated persons of members in order to comply with regulatory reporting requirements.
(2) All requests to process documentation related to an SEA Rule 10b-17 Action must be complete and submitted to the Department, in the manner and form required, no later than the time frame specified in SEA Rule 10b-17. A Requesting Party that does not submit a completed request to the Department, in the manner and form required, within the time frame specified in SEA Rule 10b-17, shall be deemed "late" and, as set forth in this Rule, subject to an additional fee before the request may be processed. Nothing in the Rule shall alter the obligations of an issuer under SEA Rule 10b-17 and the processing of documentation related to a "late" SEA Rule 10b-17 Action request by FINRA shall not relieve an issuer of any violations under such rule.
(3) All requests to process documentation related to Other Company-Related Actions must be complete and submitted to the Department, in the manner and form required, no later than the time period prescribed for such Other Company-Related Action by FINRA. Notice and information submitted for Other Company-Related Actions must be submitted no later than 10 calendar days prior to the effective date of the company action. A Requesting Party that does not submit a completed FINRA action form to the Department, in the manner and form prescribed, at least ten (10) calendar days prior to the proposed effective date of the company action, shall be deemed "late" and as set forth in this Rule, subject to an additional fee before being processed.
(4) The Department may request such additional information or documentation as may be necessary for the Department to review the request to process documentation related to an SEA Rule 10b-17 Action or Other Company-Related Action and verify the accuracy of the information submitted.
(c) Fees
The Requesting Party shall pay the following non-refundable fees for the review and processing of documentation related to an SEA Rule 10b-17 Action and Other Company-Related Action.
(d) Procedures for Reviewing Submissions
(1) Review
The Department shall review all requests to process documentation related to SEA Rule 10b-17 Actions and Other Company-Related Actions that are submitted pursuant to this Rule, including any additional documents or information requested in accordance with paragraph (b) above. All such requests must be accompanied by proof of payment of the requisite fee when appropriate in accordance with paragraph (c) above.
(2) Lapsed Requests
Where a Requesting Party does not, in the reasonable determination of the Department, sufficiently respond to any request by the Department for additional information or documentation pursuant to paragraph (b)(3) above within 90 calendar days following such Department request, such party's request shall be deemed "lapsed" and be closed.
(3) Deficiency Determination
In circumstances where an SEA Rule 10b-17 Action or Other Company-Related Action is deemed deficient, the Department may determine that it is necessary for the protection of investors, the public interest and to maintain fair and orderly markets, that documentation related to such SEA Rule 10b-17 Action or Other Company-Related Action will not be processed. In instances where the Department makes such a deficiency determination, the request to process documentation related to the SEA Rule 10b-17 Action or Other Company-Related Action, as applicable, will be closed, subject to paragraphs (d)(4) and (e) of this Rule. The Department shall make such deficiency determinations solely on the basis of one or more of the following factors: (1) FINRA staff reasonably believes the forms and all supporting documentation, in whole or in part, may not be complete, accurate or with proper authority; (2) the issuer is not current in its reporting requirements, if applicable, to the SEC or other regulatory authority; (3) FINRA has actual knowledge that the issuer, associated persons, officers, directors, transfer agent, legal adviser, promoters or other persons connected to the issuer or the SEA Rule 10b-17 Action or Other Company-Related Action are the subject of a pending, adjudicated or settled regulatory action or investigation by a federal, state or foreign regulatory agency, or a self-regulatory organization; or a civil or criminal action related to fraud or securities laws violations; (4) a state, federal or foreign authority or self-regulatory organization has provided information to FINRA, or FINRA otherwise has actual knowledge indicating that the issuer, associated persons, officers, directors, transfer agent, legal adviser, promoters or other persons connected with the issuer or the SEA Rule 10b-17 Action or Other Company-Related Action may be potentially involved in fraudulent activities related to the securities markets and/or pose a threat to public investors; and/or (5) there is significant uncertainty in the settlement and clearance process for the security.
(4) Notice Regarding Determination
If the Department determines that a request to process documentation related to a SEA Rule 10b-17 Action or a Other Company-Related Action is deficient, FINRA staff shall provide written notice to the Requesting Party. Any notice issued under this paragraph shall state the specific factor(s) that caused the request to be deemed deficient and the Requesting Party may appeal a determination pursuant to paragraph (e) of this Rule.
(5) Notice Issuance
A notice issued under this paragraph shall be issued by facsimile or electronic mail, or pursuant to Rule 9134.
(e) Request for an Appeal to Subcommittee of Uniform Practice Code Committee
A Requesting Party issued a notice under this Rule may appeal a determination made under paragraph (d)(3) of this Rule to a three-member subcommittee composed of current or former industry members of FINRA's Uniform Practice Code Committee in writing via electronic mail, unless an alternative method of service is ordered by the Adjudicator, within seven calendar days after service of the notice. Service of the appeal by electronic mail shall be deemed complete upon sending. The written request for an appeal must be accompanied by proof of payment of the non-refundable Action Determination Appeal Fee. A request for an appeal must set forth with specificity any and all defenses to the Department's determination that a request was unacceptable or otherwise deficient. An appeal to the subcommittee shall operate to stay the processing of the company-related action (i.e., the requested company-related action shall not be processed during the period that the Requesting Party requests an appeal or while any such appeal is pending). Once a written appeal has been received, the Requesting Party may submit any additional supporting written documentation via electronic mail, unless an alternative method of service is ordered by the Adjudicator, up until the time the appeal is considered by the subcommittee. The subcommittee shall convene once each calendar month to consider all appeals received under this Rule during the prior month. The subcommittee shall render a determination within three business days following the day the appeal is considered by the subcommittee. The subcommittee's determination shall constitute final action by FINRA. The subcommittee's determination shall not constitute an estoppel as to FINRA nor bind FINRA in any subsequent administrative, civil, or disciplinary proceeding. If the Requesting Party fails to file a written request for an appeal within seven calendar days after service of the notice by the Department, the Department's determination shall constitute final action by FINRA.
Below are General Questions related to Deficiency Determinations:
8. How will I know if my Company-Related Action was processed or found deficient?
FINRA will provide a written notice to the requesting party setting forth the outcome of FINRA’s review. In addition, if FINRA determines that the request will not be processed pursuant to FINRA Rule 6490(d)(3), the written notice will state the specific factor(s) that caused the request to be deemed deficient.
9. Is a FINRA Rule 6490 Company-Related Action deficiency determination a matter of public record?
No. FINRA does not publicly announce deficiency determinations relating to a Company-Related Action.
10. Will I be informed of a potential deficiency before a deficiency determination letter is issued?
Yes. Department staff will inform a requesting party of a potential deficiency before a deficiency determination is issued. The requesting party may provide the Department staff with any additional documentation intended to address the potential deficiency basis.
11. Can I appeal a deficiency determination?
Yes. A requesting party may appeal a deficiency determination within seven calendar days after service of the notice of a deficiency determination by FINRA. The written request for an appeal must be accompanied by proof of payment of the non-refundable Action Determination Appeal Fee ($4,000) and must set forth with specificity any and all defenses to the deficiency determination.
An appeal will operate to stay the processing of the Company-Related Action (i.e., the requested Company-Related Action will not be processed during the period that the requesting party’s appeal is pending). A requesting party may submit any additional supporting written documentation up until the time the appeal is considered by the subcommittee (see question 12 below for more information about the subcommittee). The subcommittee will consider the appeal based solely on the written documents submitted by the requesting party and FINRA. The submission of new facts that address the concerns in the deficiency letter, however, will not serve as a basis to reverse the Department’s decision. If there are new facts that FINRA is requested to consider in reviewing the Company-Related Action request, the requesting party should submit that information to the Department as part of a new request.
Please see Rule 6490(e) (Request for an Appeal to Subcommittee of Uniform Practice Code Committee) for additional information on the appeal process.
12. Who reviews deficiency appeals under FINRA Rule 6490?
Appeals of a deficiency determination under FINRA Rule 6490 are reviewed by a three-member subcommittee comprised of current or former industry members of FINRA’s Uniform Practice Code Committee.
13. When can I expect my appeal to be reviewed by the subcommittee?
The subcommittee convenes once each calendar month to consider all appeals received during the prior month and renders a determination within three business days following the day the appeal is considered. The subcommittee’s determination constitutes final FINRA action.
14. Am I required to file an appeal to a FINRA Rule 6490(d) deficiency determination?
No. A requesting party is not required to appeal a deficiency finding. If a requesting party does not appeal a deficiency finding, the Department will not announce the requesting party’s Company Related Action.
A lot of low priced therapeutic stocks are going back up this month on high volume trading, so the vibe seems to be a good leading indicator for SBFM to follow in the not too distant future. If SBFM continues the buyback and puts out some positive news within the next couple of months I think a return to the $2-5 price range is possible by the end of 2023. Based on this vibe I'm accumulating a bit more SBFM in the sub $1 range.
PS: Note that SBFM has recently updated their website so I think their IR/PR firm (TraDigital) is getting them ready for some growth.
Are they running it from their HQ in New York..........
Address: EXXE Group 1345 Avenue of the Americas, 2nd Floor, New York, NY 10105
Wrong...it is a 4-bit Vitamin and Prescription Drug Reseller.....and an 8-bit COVID and CANCER Drug Developer!
How many shares of it do you own?
How long have you been following this dangling carrot? Looks like about 21 days and 19 posts. How much longer will you follow?
So maybe $.30 this year, $1 next year, then up from there. Looking forward to where AXXA lands in 2023.
Hi. In what year will AXXA hit $5?
Excellent SBFM 2022 Annual Report and Recent Highlights.....looking forward to 2023 and beyond!
Full Year 2022 and Recent Highlights:
-- Listing on NASDAQ.
-- Bolstered balance sheet with cash and cash and cash equivalents of $21
million.
-- Acquisition of Nora Pharma Inc. in October 2022, giving the Company 49
prescription drugs on the market in Canada.
-- Expansion of proprietary drug development program including the signing
of agreements with the University of Arizona for SBFM-PL4 COVID-19
treatment and the Jewish General Hospital (Montreal, Canada) for
IND-enabling studies of Adva-27a anticancer compound.
-- Advancing the development of the Company's anticancer K1.1 mRNA program
by entering into collaboration and testing agreement with one of the
leading lipid nanoparticle formulation companies in North America.
-- Increased sales from $228,426 in 2021 to $4,345,603 in 2022, largely due
to inclusion of the 72 days of Nora Pharma operations, the time since the
closing of the acquisition.
I see that CCAJ also addressed the lack of communication on Twitter on March 31, 2023 and referred everyone to their website for updates. I don't see anything about the properties there yet, so hopefully soon.
CCAJ Twitter: https://twitter.com/ccajstock/with_replies
CCAJ Website: https://coastalcapitalacquisitioncorp.com/investor-relations/
$.07, $.35, $.75, $1.00 all sound good....let's see where 2023 lands.
"ResearchThis" predicts $1.00 and my Crystal Ball says somewhere between $.10-1.00
I'm listening to my Crystal Ball which tells me 2023 is the turnaround year. Let's see where AXXA lands by December 31, 2023....at either $.001 or $1.00 or somewhere in between!
Give it 6-9 more months. After all these years that shouldn't be too much to ask. By then we should know for sure about that status of the Covid treatment and the cancer treatment (both are supposed to start additional trials this year). By then, you'll also know for sure about delisting (or not delisting)!
That is my timeline and if things are improving I'll stick around another year or so.
The CCAJ asset numbers look good with substantial increase year over year:
Total Assets: $ 16,256,853 (as of 12/31/22)
$ 2,562,120 (as of 12/31/21)
Thanks for the SEC update keeping CCAJ honest.
Yes, and if I recall correctly CCAJ had some property identified to build on. It would be good to see the foundations!
Anywhere between $.10-1.00 works for my piece of the pie!
CCAJ filed Annual Report today. Nothing new so seems like they aren't doing much, but will stay Pink Current. Let us know if anything comes from the SEC.
Why did SBFM go up 7% afterhours? This is not typical.
I'll be content with a return to $.10 this year. $.10+ is gravy for me.
New CCAJ/CCAC Website: https://coastalcapitalacquisitioncorp.com/
Thanks, except for the new website they have been silent about any activity since December. Prior to that they were also silent from June-December so it seems as though they are either doing things they can't announce yet or they aren't doing anything except creating a new website.
What is the window of time you are referring too before shareholders can make "millions?" Is it 1 year, 2 years, 5 years? I'm curious how much patience you have?
I've got some cash lined up if the dumpsters are done and the Annual Report has anything good in it!
Will we see the CCAJ Annual Report on March 30, 2023?
Are the CCAJ dumpsters done yet?
SBFM progress pipeline (October 2022-February 2023):
1. PLpro-based COVID Treatment (signed agreement with UoA in February 2023)
2. Adva-27a Cancer Treatment (signed agreement with Jewish General Hospital/McGill U in February 2023)
3. Share Repurchase Program (authorized in January 2023)
4. K1.1 mRNA-based LNP Cancer Treatment (entered collaboration agreement with a leading LNP company in November 2022)
5. Growing Nora Pharma, Inc. (acquired in October 2022)
I'm here until December 31, 2023 or $.25, whichever comes first! To whoever controls the PPS, let it be $.25
Well, it is time for SBFM to move back to the $10-20 range in 2023 and higher in 2024 and perhaps higher in 2025!
Don't forget they are progressing on:
1. PLpro-based COVID Treatment
2. Adva-27a Cancer Treatment
3. K1.1 mRNA-based LNP Cancer Treatment
And they acquired Nora Pharma, Inc. and announced a Share Repurchase program within the past 3-6 months.
By multi-year I meant 2023-2025. SBFM may go up from here beginning any day, week or month from now and gradually increase to the multi-dollars range.
From the recent NEWS, looks like SBFM will be a multi-year potential money-making stock from these lows. Not sure when it will go up next, but they have definitely lined up the clinical research pathway for both Cancer (McGill U) and Covid (UoA). As they progress I do believe dollars per share are on the horizon.
I am planning to buy a few more shares in the coming days, and good luck to those who stick around and those who don't.
Thanks. I guess we'll get the answer in writing from CCAJ at some point.
Let's see your simple math on when the PPS will rise from the ashes........
What + What = a much higher PPS
Thanks. Your explanation was quite informative.
Sounds like it might work, but we'll see. I'm planning to hold on in 2023, but the past year and a half was a long downward path in terms of the PPS.
If AXXA is doing all the right things then why did the PPS go from over $.08 in late 2021 to $.0068 now? Or, did they not do the right things to protect shareholder value? Please explain.
No, I'm saying AXXA should use funds to buy from the open market and then take the shares out of circulation. That would make the PPS rise so they likely wouldn't get amount of shares I estimated. Nonetheless, the impact on the PPS would likely generate more new investor enthusiasm than what they have been doing. Just a common sense thought based on supply and demand! Currently there is too much supply of shares and not enough demand to push the price higher. That is what AXXA needs to fix and I don't see a plan for that.